AS 1409

Drug Profile

AS 1409

Alternative Names: Antibody-cytokine fusion drug (AS1409); AS-1409; BC1-IL-12; hBC1-hIL-12; huBC1/IL-12 fusion protein; huBC1/IL12 fusion drug; Tumour-targeting antibody BC1/IL-12 fusion drug

Latest Information Update: 19 Jul 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Antisoma; EMD Lexigen
  • Developer Antisoma
  • Class Antibodies; Antineoplastics; Interleukins; Monoclonal antibodies
  • Mechanism of Action Interferon gamma stimulants; Natural killer cell stimulants; Th1 cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Malignant melanoma; Renal cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 11 Jan 2012 Discontinued - Phase-I for Malignant melanoma in New Zealand (IV)
  • 11 Jan 2012 Discontinued - Phase-I for Malignant melanoma in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top